APO RESEARCH · REPORT
Paclitaxel
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
Product & engineering
Understand the product.
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
Selected research
Industry Research
Paclitaxel Industry Research Report 2026
Market perspective
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
North America and China are the largest producer of Paclitaxel, with a market share about 35% separately. Phyton, ScinoPharm, Huiang biopharma, Southpharma and Novasep are the top 5 manufacturers of industry, and they had more than 60% combined market share.
Report Scope
Read the full market overview
This report quantifies the global Paclitaxel market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Paclitaxel Market by Company
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology
Paclitaxel Segment by Type
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
Paclitaxel Segment by Application
Ovarian Cancer
Cervical Cancer
Breast Cancer
Others
Paclitaxel Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paclitaxel market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Paclitaxel and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paclitaxel.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Paclitaxel manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Paclitaxel by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Paclitaxel in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Natural Paclitaxel API
- Semi-synthetic Paclitaxel API
Applications
- Ovarian Cancer
- Cervical Cancer
- Breast Cancer
- Others
Companies covered
- Phyton
- ScinoPharm
- Novasep
- Samyang
- Polymed
- TAPI (Teva)
- Fresenius-kabi
- Huiang biopharma
- Southpharma
- Yunnan Hande
- Hainan Yew Pharm
- Jiangsu Yew Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Paclitaxel Market Size (2021-2032)
- 2.2.2 Global Paclitaxel Sales (2021-2032)
- 2.2.3 Global Paclitaxel Market Average Price (2021-2032)
- 2.3 Paclitaxel by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Natural Paclitaxel API
- 2.3.3 Semi-synthetic Paclitaxel API
- 2.4 Paclitaxel by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ovarian Cancer
- 2.4.3 Cervical Cancer
- 2.4.4 Breast Cancer
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Paclitaxel Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Paclitaxel Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Paclitaxel Revenue of Manufacturers (2021-2026)
- 3.4 Global Paclitaxel Average Price by Manufacturers (2021-2026)
- 3.5 Global Paclitaxel Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Paclitaxel, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Paclitaxel, Product Type & Application
- 3.8 Global Manufacturers of Paclitaxel, Established Date
- 3.9 Global Paclitaxel Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Phyton
- 4.1.1 Phyton Company Information
- 4.1.2 Phyton Business Overview
- 4.1.3 Phyton Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Phyton Paclitaxel Product Portfolio
- 4.1.5 Phyton Recent Developments
- 4.2 ScinoPharm
- 4.2.1 ScinoPharm Company Information
- 4.2.2 ScinoPharm Business Overview
- 4.2.3 ScinoPharm Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 ScinoPharm Paclitaxel Product Portfolio
- 4.2.5 ScinoPharm Recent Developments
- 4.3 Novasep
- 4.3.1 Novasep Company Information
- 4.3.2 Novasep Business Overview
- 4.3.3 Novasep Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novasep Paclitaxel Product Portfolio
- 4.3.5 Novasep Recent Developments
- 4.4 Samyang
- 4.4.1 Samyang Company Information
- 4.4.2 Samyang Business Overview
- 4.4.3 Samyang Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Samyang Paclitaxel Product Portfolio
- 4.4.5 Samyang Recent Developments
- 4.5 Polymed
- 4.5.1 Polymed Company Information
- 4.5.2 Polymed Business Overview
- 4.5.3 Polymed Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Polymed Paclitaxel Product Portfolio
- 4.5.5 Polymed Recent Developments
- 4.6 TAPI (Teva)
- 4.6.1 TAPI (Teva) Company Information
- 4.6.2 TAPI (Teva) Business Overview
- 4.6.3 TAPI (Teva) Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 TAPI (Teva) Paclitaxel Product Portfolio
- 4.6.5 TAPI (Teva) Recent Developments
- 4.7 Fresenius-kabi
- 4.7.1 Fresenius-kabi Company Information
- 4.7.2 Fresenius-kabi Business Overview
- 4.7.3 Fresenius-kabi Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Fresenius-kabi Paclitaxel Product Portfolio
- 4.7.5 Fresenius-kabi Recent Developments
- 4.8 Huiang biopharma
- 4.8.1 Huiang biopharma Company Information
- 4.8.2 Huiang biopharma Business Overview
- 4.8.3 Huiang biopharma Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Huiang biopharma Paclitaxel Product Portfolio
- 4.8.5 Huiang biopharma Recent Developments
- 4.9 Southpharma
- 4.9.1 Southpharma Company Information
- 4.9.2 Southpharma Business Overview
- 4.9.3 Southpharma Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Southpharma Paclitaxel Product Portfolio
- 4.9.5 Southpharma Recent Developments
- 4.10 Yunnan Hande
- 4.10.1 Yunnan Hande Company Information
- 4.10.2 Yunnan Hande Business Overview
- 4.10.3 Yunnan Hande Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Yunnan Hande Paclitaxel Product Portfolio
- 4.10.5 Yunnan Hande Recent Developments
- 4.11 Hainan Yew Pharm
- 4.11.1 Hainan Yew Pharm Company Information
- 4.11.2 Hainan Yew Pharm Business Overview
- 4.11.3 Hainan Yew Pharm Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hainan Yew Pharm Paclitaxel Product Portfolio
- 4.11.5 Hainan Yew Pharm Recent Developments
- 4.12 Jiangsu Yew Biotechnology
- 4.12.1 Jiangsu Yew Biotechnology Company Information
- 4.12.2 Jiangsu Yew Biotechnology Business Overview
- 4.12.3 Jiangsu Yew Biotechnology Paclitaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Jiangsu Yew Biotechnology Paclitaxel Product Portfolio
- 4.12.5 Jiangsu Yew Biotechnology Recent Developments
5 Global Paclitaxel Market Scenario by Region
- 5.1 Global Paclitaxel Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Paclitaxel Sales by Region: 2021-2032
- 5.2.1 Global Paclitaxel Sales by Region: 2021-2026
- 5.2.2 Global Paclitaxel Sales by Region: 2027-2032
- 5.3 Global Paclitaxel Revenue by Region: 2021-2032
- 5.3.1 Global Paclitaxel Revenue by Region: 2021-2026
- 5.3.2 Global Paclitaxel Revenue by Region: 2027-2032
- 5.4 North America Paclitaxel Market Facts & Figures by Country
- 5.4.1 North America Paclitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Paclitaxel Sales by Country (2021-2032)
- 5.4.3 North America Paclitaxel Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Paclitaxel Market Facts & Figures by Country
- 5.5.1 Europe Paclitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Paclitaxel Sales by Country (2021-2032)
- 5.5.3 Europe Paclitaxel Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Paclitaxel Market Facts & Figures by Country
- 5.6.1 Asia Pacific Paclitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Paclitaxel Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Paclitaxel Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Paclitaxel Market Facts & Figures by Country
- 5.7.1 South America Paclitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Paclitaxel Sales by Country (2021-2032)
- 5.7.3 South America Paclitaxel Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Paclitaxel Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Paclitaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Paclitaxel Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Paclitaxel Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Paclitaxel Sales by Type (2021-2032)
- 6.1.1 Global Paclitaxel Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Paclitaxel Sales Market Share by Type (2021-2032)
- 6.2 Global Paclitaxel Revenue by Type (2021-2032)
- 6.2.1 Global Paclitaxel Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Paclitaxel Revenue Market Share by Type (2021-2032)
- 6.3 Global Paclitaxel Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Paclitaxel Sales by Application (2021-2032)
- 7.1.1 Global Paclitaxel Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Paclitaxel Sales Market Share by Application (2021-2032)
- 7.2 Global Paclitaxel Revenue by Application (2021-2032)
- 7.2.1 Global Paclitaxel Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Paclitaxel Revenue Market Share by Application (2021-2032)
- 7.3 Global Paclitaxel Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Paclitaxel Value Chain Analysis
- 8.1.1 Paclitaxel Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Paclitaxel Production Mode & Process
- 8.2 Paclitaxel Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Paclitaxel Distributors
- 8.2.3 Paclitaxel Customers
9 Global Paclitaxel Analyzing Market Dynamics
- 9.1 Paclitaxel Industry Trends
- 9.2 Paclitaxel Industry Drivers
- 9.3 Paclitaxel Industry Opportunities and Challenges
- 9.4 Paclitaxel Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst